Heart Test Laboratories EBIT

Heart Test Laboratories's ebit stands at $-1.9B as of January 2026. That compares with $-6.4B in the prior-year period — up 70.8% year over year. That is below the sector sector average of $-6.4M. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Heart Test Laboratories reported $-1.9B in EBIT versus $-6.4B a year earlier — a 70.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Heart Test Laboratories sits lower the its sector benchmark ($-6.4M) with a EBIT of $-1.9B. That is roughly 29265.2% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-6.4B in the prior-year period — up 70.8% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Heart Test Laboratories's EBIT evolved across reporting periods, while the comparison chart places HSCS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.